FORM 3
        	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
	OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

Kirson Eilon D.	2. Date of Event Requiring Statement (MM/DD/YYYY)
10/1/2015 
	3. Issuer Name and Ticker or Trading Symbol

Novocure Ltd [NVCR]	
(Last)        (First)        (Middle)

C/O NOVOCURE INC., 20 VALLEY STREAM PKWY, SUITE 300	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Chief Science Officer /	
(Street)

MALVERN, PA 19355       

(City)              (State)              (Zip)	5. If Amendment, Date Original Filed (MM/DD/YYYY)

	6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned	
1.Title of Security
(Instr. 4)	2. Amount of Securities Beneficially Owned
(Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)	4. Nature of Indirect Beneficial Ownership
(Instr. 5)	
Ordinary Shares  	148445  	D  	 	

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 4)	2. Date Exercisable and Expiration Date
(MM/DD/YYYY)	3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)	6. Nature of Indirect Beneficial Ownership
(Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Options to Buy Ordinary Shares  	  (1)	5/1/2016  	Ordinary Shares  	29565  	$0.17  	D  	 	
Options to Buy Ordinary Shares  	  (1)	12/12/2016  	Ordinary Shares  	156073  	$0.17  	D  	 	
Options to Buy Ordinary Shares  	  (1)	9/15/2021  	Ordinary Shares  	76869  	$3.44  	D  	 	
Options to Buy Ordinary Shares  	  (2)	12/14/2021  	Ordinary Shares  	70956  	$3.44  	D  	 	
Options to Buy Ordinary Shares  	  (3)	2/20/2013  	Ordinary Shares  	218781  	$7.03  	D  	 	
Options to Buy Ordinary Shares  	  (4)	2/26/2024  	Ordinary Shares  	59130  	$7.48  	D  	 	
Options to Buy Ordinary Shares  	  (5)	2/25/2025  	Ordinary Shares  	266085  	$14.37  	D  	 	

Explanation of Responses:	
(  1) 	Fully vested and currently exercisable as of the date hereof.	
(  2) 	Options to buy 53,217 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 17,739 ordinary shares will vest and become exercisable on December 14, 2015, subject to Mr. Kirson's continued employment through such date.	
(  3) 	Options to buy 109,390 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 109,391 ordinary shares will vest and become exercisable in equal installments on each of February 20, 2016 and 2017, subject to Mr. Kirson's continued employment through such dates.	
(  4) 	Options to buy 14,782 ordinary shares are vested and currently exercisable as of the date hereof. The remaining options to buy 44,348 ordinary shares will vest and become exercisable in equal installments on each of February 26, 2016, 2017 and 2018, subject to Mr. Krison's continued employment through such dates.	
(  5) 	The options to buy 266,085 ordinary shares will vest and become exercisable in equal installments on each of February 25, 2016, 2017, 2018 and 2019, subject to Mr. Kirson's continued employment through such dates.	

Remarks:
Exhibit 24 - Power of Attorney	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
Kirson Eilon D.
C/O NOVOCURE INC., 20 VALLEY STREAM PKWY
SUITE 300
MALVERN, PA 19355			Chief Science Officer		

Signatures		
/s/ Todd Longsworth, Attorney in fact for Eilon Kirson		10/1/2015	
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	

                          LIMITED POWER OF ATTORNEY FOR
                          SECTION 16 REPORTING PURPOSES

     Know all by these presents, that the undersigned hereby makes, constitutes
and appoints Todd Longsworth, acting individually, as the undersigned's true and
lawful attorney-in-fact, with full power and authority as hereinafter described
on behalf of and in the name, place and stead of the undersigned to:

     (1)  execute for, and on behalf of, the undersigned, in the undersigned's
capacity as an officer, director and/or 10% beneficial owner of Novocure Limited
(the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934 and the rules and regulations promulgated
thereunder (the "Exchange Act");

     (2)  seek or obtain, as the undersigned's representative and on the
undersigned's behalf, information on transactions in the Company's securities
from any third party, including brokers, employee benefit plan administrators
and trustees, and the undersigned hereby authorizes any such person to release
any such information to any attorney-in-fact and further approves and ratifies
any such release of information;

     (3)  do and perform any and all acts for and on behalf of the undersigned
that may be necessary or desirable to prepare, complete and execute any such
Form 3, 4 or 5, and any amendments thereto, or other required report and timely
file such Forms or reports with the United States Securities and Exchange
Commission, the New York Stock Exchange and any stock exchange or similar
authority as considered necessary or advisable under Section 16(a) of the
Exchange Act; and

     (4)  take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Limited Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's sole discretion.

     The undersigned hereby gives and grants to each such attorney-in-fact full
power and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.

     The undersigned hereby acknowledges that (a) the foregoing
attorneys-in-fact are serving in such capacity at the request of the
undersigned; (b) this Limited Power of Attorney authorizes, but does not
require, each such attorney-in-fact to act in his or her discretion on
information provided to such attorney-in-fact without independent verification
of such information; (c) any documents prepared and/or executed by any
attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of
Attorney shall be in such form and shall contain such information and disclosure
as such attorney-in-fact, in his or her sole discretion, deems necessary or
advisable; (d) neither the Company nor any attorney-in-fact assumes (i) any
liability for the undersigned's responsibility to comply with the requirements
of the Exchange Act, (ii) any liability of the undersigned for any failure to
comply with such requirements or (iii) any obligation or liability of the
undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and
(e) this Limited Power of Attorney does not relieve the undersigned from
responsibility for compliance with the undersigned's obligations under the
Exchange Act, including, without limitation, the reporting requirements under
Section 16 of the Exchange Act.

     This Limited Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file Forms 3, 4, and 5 with respect to
the undersigned's holdings of, and transactions in, securities issued by the
Company, unless earlier revoked as to any attorney-in-fact by the undersigned in
a signed writing delivered to such attorney-in-fact.

     IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 14 day of September, 2015.

                                          /s/ Eilon Kirson
                                        ----------------------------------
                                                         Signature

                                             Eilon Kirson
                                        ----------------------------------
                                                         Print Name